The effect of dextromethorphan in the treatment of depression

Dextromethorphan as an adjuvant therapy to sertraline in major depressive disorder: A randomized, double-blind, placebo-controlled trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20090117001556N160

Enrollment

Registered

2024-07-23

Start date

2024-09-22

Completion date

Unknown

Last updated

2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major depressive disorder. Major depressive disorder, single episode

Interventions

Intervention 1: Intervention group: sertraline tablet at a dose of 100 mg/day once a day and dextromethorphan at a dose of 30 mg three times a dayfor six weeks. Intervention 2: Control group: sertrali

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age between 18-65 Diagnosis of major depressive disorder based on DSM-V (score between 14 and 17).

Exclusion criteria

Exclusion criteria: Serious suicidal thoughts psychosis co-occurring psychiatric disorder such as bipolar disorder, schizophrenia alcohol and drug use disorders personality disorder ECT in the last two months thyroid problems history of cardiovascular disease diabetes autoimmune disease active infection neurological diseases (epilepsy, stroke, dementia), hematology, liver and kidney diseases cancer pregnancy and breastfeeding

Design outcomes

Primary

Measure	Time frame
Severity of depression. Timepoint: Weeks: 0, 2, 4 and 6. Method of measurement: By Hamilton Depression Rating Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Shahin Akhondzadeh

Tehran University of Medical Sciences

s.akhond@sina.tums.ac.ir+98 21 5541 2222

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026